Rosiglitazone does not raise heart risk in diabetes

07/23/2013 | MedPage Today (free registration)

Rosiglitazone did not appear to increase the risk of major cardiac events and death in diabetes patients with coronary artery disease compared with patients not taking a thiazolidinedione-based drug, according to an analysis in the journal Circulation. Researchers also found a lower incidence of the composite of death, myocardial infarction and stroke in patients taking rosiglitazone.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC